Nele Fourneau

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cancer stem cells revisited

Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites

Targeting apoptosis in cancer therapy

Epigenetic treatment of solid tumours: a review of clinical trials

Macrophages are critical effectors of antibody therapies for cancer

Diffuse large B-cell lymphoma—treatment approaches in the molecular era

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study

Tumour-associated macrophages as treatment targets in oncology

Precision glycocalyx editing as a strategy for cancer immunotherapy

HDACs and HDAC Inhibitors in Cancer Development and Therapy

A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL).